A detailed history of Legal & General Group PLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 254,641 shares of ARWR stock, worth $5.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
254,641
Previous 254,641 -0.0%
Holding current value
$5.18 Million
Previous $4.93 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.36 - $29.54 $17,985 - $27,442
929 Added 0.37%
254,641 $4.93 Million
Q2 2024

Aug 14, 2024

SELL
$21.87 - $28.24 $444,792 - $574,345
-20,338 Reduced 7.42%
253,712 $6.59 Million
Q1 2024

May 14, 2024

SELL
$27.21 - $39.48 $43,182 - $62,654
-1,587 Reduced 0.58%
274,050 $7.84 Million
Q4 2023

Feb 15, 2024

BUY
$21.2 - $31.03 $1.21 Million - $1.77 Million
57,167 Added 26.17%
275,637 $8.43 Million
Q3 2023

Nov 14, 2023

SELL
$26.2 - $36.08 $118,031 - $162,540
-4,505 Reduced 2.02%
218,470 $5.87 Million
Q2 2023

Aug 14, 2023

SELL
$25.16 - $41.38 $223,622 - $367,785
-8,888 Reduced 3.83%
222,975 $7.95 Million
Q1 2023

May 15, 2023

SELL
$23.68 - $38.51 $1.12 Million - $1.83 Million
-47,478 Reduced 17.0%
231,863 $5.89 Million
Q4 2022

Feb 14, 2023

BUY
$28.0 - $40.56 $340,704 - $493,534
12,168 Added 4.55%
279,341 $11.3 Million
Q3 2022

Nov 14, 2022

SELL
$29.63 - $48.31 $48,119 - $78,455
-1,624 Reduced 0.6%
267,173 $8.83 Million
Q2 2022

Aug 22, 2022

BUY
$27.79 - $50.61 $365,549 - $665,723
13,154 Added 5.15%
268,797 $9.47 Million
Q1 2022

May 16, 2022

BUY
$39.62 - $69.97 $1.11 Million - $1.95 Million
27,937 Added 12.27%
255,643 $11.8 Million
Q4 2021

Feb 14, 2022

BUY
$58.09 - $82.51 $212,667 - $302,069
3,661 Added 1.63%
227,706 $15.1 Million
Q3 2021

Nov 15, 2021

BUY
$58.38 - $84.96 $1.36 Million - $1.98 Million
23,310 Added 11.61%
224,045 $14 Million
Q2 2021

Aug 12, 2021

SELL
$62.15 - $90.32 $5.47 Million - $7.95 Million
-87,997 Reduced 30.48%
200,735 $16.6 Million
Q1 2021

May 17, 2021

BUY
$61.35 - $90.47 $2.39 Million - $3.52 Million
38,953 Added 15.59%
288,732 $19.1 Million
Q4 2020

Feb 12, 2021

BUY
$43.82 - $85.37 $342,497 - $667,251
7,816 Added 3.23%
249,779 $19.2 Million
Q3 2020

Nov 13, 2020

SELL
$33.21 - $51.27 $66,121 - $102,078
-1,991 Reduced 0.82%
241,963 $10.4 Million
Q2 2020

Aug 14, 2020

BUY
$26.12 - $43.27 $2.71 Million - $4.49 Million
103,851 Added 74.12%
243,954 $10.5 Million
Q1 2020

May 14, 2020

SELL
$20.56 - $63.12 $14,165 - $43,489
-689 Reduced 0.49%
140,103 $4.03 Million
Q4 2019

Feb 13, 2020

SELL
$28.14 - $73.01 $3.77 Million - $9.77 Million
-133,870 Reduced 48.74%
140,792 $8.93 Million
Q3 2019

Nov 13, 2019

BUY
$26.26 - $34.86 $1.34 Million - $1.78 Million
51,159 Added 22.89%
274,662 $7.74 Million
Q2 2019

Aug 14, 2019

BUY
$17.43 - $28.82 $3.59 Million - $5.93 Million
205,780 Added 1161.09%
223,503 $5.92 Million
Q1 2019

May 15, 2019

BUY
$12.05 - $20.18 $28,136 - $47,120
2,335 Added 15.17%
17,723 $325,000
Q4 2018

Feb 15, 2019

BUY
$10.74 - $19.7 $17,377 - $31,874
1,618 Added 11.75%
15,388 $191,000
Q2 2018

Aug 10, 2018

BUY
$6.37 - $14.02 $87,714 - $193,055
13,770 New
13,770 $188,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.16B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.